[33A5-33A5];[33C1-33C1];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
33A5;33C1
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
Inferred to overlap with: Df(2L)Exel6030.
Inferred to overlap with: Df(2L)Exel6031.
Df(2L)BSC323 is homozygous lethal.
The presence of P+PBac{XP5.WH5}BSC323 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of P{XP}d10374 to be at Release 3 genomic coordinate 12044040 on chromosome arm 2L. The Gene Disruption project determined the insertion site of P{XP}d10374 to be at Release 3 genomic coordinate 12044441 on arm 2L. This corresponds to 33C1 on both the Release 3 and 5 genome maps. The predicted position of PBac{WH}CG31757f02409 on the Release 5 map is 33A5. Consequently, the cytological breakpoints of Df(2L)BSC323 are predicted to be 33A5;33C1.